Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
NCT ID: NCT00189722
Last Updated: 2008-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
160 participants
INTERVENTIONAL
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients treated with inhaled corticosteroid and long acting beta 2 agonist
* FEV1(forced expiratory volume in 1 second)\>50% to 80%
Exclusion Criteria
* Asthma exacerbation within 6 weeks
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R. G. M. vom Amsterdam, MD
Role: STUDY_DIRECTOR
Astellas Pharma Europe B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brno, , Czechia
Krhanice, , Czechia
Olomouc, , Czechia
Šumperk, , Czechia
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Deggendort, , Germany
Hamburg, , Germany
Hanover, , Germany
München, , Germany
Rudersdorf, , Germany
Wiesbaden, , Germany
Bialystok, , Poland
Krakow, , Poland
Lodz, , Poland
Lublin, , Poland
Tarnów, , Poland
Wroclaw, , Poland
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Smolensk, , Russia
Yekaterinburg, , Russia
Dnipro, , Ukraine
Kiev, , Ukraine
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FG-506-17-05
Identifier Type: -
Identifier Source: org_study_id